MacroGenics Inc
NASDAQ:MGNX
Intrinsic Value
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of c... [ Read More ]
The intrinsic value of one MGNX stock under the Base Case scenario is 5.48 USD. Compared to the current market price of 16.07 USD, MacroGenics Inc is Overvalued by 66%.
Valuation Backtest
MacroGenics Inc
Run backtest to discover the historical profit from buying and selling MGNX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
MacroGenics Inc
Current Assets | 251.3m |
Cash & Short-Term Investments | 229.8m |
Receivables | 10.4m |
Other Current Assets | 11.2m |
Non-Current Assets | 47.1m |
PP&E | 45.7m |
Other Non-Current Assets | 1.4m |
Current Liabilities | 56.1m |
Accounts Payable | 6.4m |
Accrued Liabilities | 28m |
Other Current Liabilities | 21.7m |
Non-Current Liabilities | 89.7m |
Other Non-Current Liabilities | 89.7m |
Earnings Waterfall
MacroGenics Inc
Revenue
|
58.7m
USD
|
Cost of Revenue
|
-8.2m
USD
|
Gross Profit
|
50.5m
USD
|
Operating Expenses
|
-218.8m
USD
|
Operating Income
|
-168.2m
USD
|
Other Expenses
|
159.2m
USD
|
Net Income
|
-9.1m
USD
|
Free Cash Flow Analysis
MacroGenics Inc
What is Free Cash Flow?
MGNX Profitability Score
Profitability Due Diligence
MacroGenics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
MacroGenics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
MGNX Solvency Score
Solvency Due Diligence
MacroGenics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
MacroGenics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MGNX Price Targets Summary
MacroGenics Inc
According to Wall Street analysts, the average 1-year price target for MGNX is 25.27 USD with a low forecast of 16.16 USD and a high forecast of 31.5 USD.
Ownership
MGNX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MGNX Price
MacroGenics Inc
Average Annual Return | -3.55% |
Standard Deviation of Annual Returns | 74.79% |
Max Drawdown | -94% |
Market Capitalization | 997.5m USD |
Shares Outstanding | 62 432 000 |
Percentage of Shares Shorted | 12.65% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 427 full-time employees. The company went IPO on 2013-10-10. The company is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. The company is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.
Contact
IPO
Employees
Officers
The intrinsic value of one MGNX stock under the Base Case scenario is 5.48 USD.
Compared to the current market price of 16.07 USD, MacroGenics Inc is Overvalued by 66%.